RxDoctor Payments Data

Alexis Weinrich

Physician Assistant · Walla Walla, WANPI 1134834690

Payments from drug & device makers

$1,286in general payments, 2019–2025

Across 67 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$394
  • Abbott$134
  • Amgen$113
  • Lilly USA, LLC$100
  • AstraZeneca$99
  • Insulet Corporation$88
  • plus $358 from 10 others

What the payments were for

  • Food & beverage$1,286100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,286 in reported general payments places this provider in the 85th percentile of 2,741 physician assistant providers in Washington.

See all physician assistant providers in Washington

Medicare billing

Part B allowed, 2024
$107,783
Medicare patients
211
Services billed
7,372

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide150$201,023
JardianceEmpagliflozin139$155,988
TrulicityDulaglutide61$88,874
Tresiba Flextouch U-100Insulin Degludec54$35,312
JanuviaSitagliptin Phosphate24$14,320
KerendiaFinerenone17$13,620
Lantus SolostarInsulin Glargine,hum.Rec.Anlog89$13,539
FarxigaDapagliflozin Propanediol17$12,401
Novolog FlexpenInsulin Aspart28$10,105
Semglee (Yfgn) PenInsulin Glargine-Yfgn16$8,909
Humalog Kwikpen U-100Insulin Lispro30$5,904
Nano 2nd Gen Pen NeedlePen Needle, Diabetic27$2,221
Levothyroxine Sodium129$1,480
Repaglinide46$1,464
Liothyronine Sodium33$1,070

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$394$201,023150 claims
Boehringer IngelheimJardiance$44$155,988139 claims
Lilly USA, LLCTrulicity$100$88,87461 claims
BayerKerendia$83$13,62017 claims
AstraZenecaFarxiga$99$12,40117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,741 physician assistant providers in Washington.

Other physician assistant in Walla Walla

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →